{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T01:15:45Z","timestamp":1788225345049,"version":"build-2803163510"},"reference-count":81,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010481","name":"Etablissement Fran\u00e7ais du Sang","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010481","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018872","name":"Labex Immuno-Oncologie","doi-asserted-by":"publisher","award":["ANR-11-LABX-570 0021-LipSTIC"],"award-info":[{"award-number":["ANR-11-LABX-570 0021-LipSTIC"]}],"id":[{"id":"10.13039\/501100018872","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015679","name":"University of Tlemcen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015679","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019915","name":"Scottish Aquaculture Innovation Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005307","name":"Algeria Directorate General for Scientific Research and Technological Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005307","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.isci.2026.116323","type":"journal-article","created":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T16:55:00Z","timestamp":1781456100000},"page":"116323","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metformin dual-targets metabolism and survival pathways in BPDCN"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0683-777X","authenticated-orcid":false,"given":"Zineb","family":"Mekkaoui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludivine","family":"Dal Zuffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Fredon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Poussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeha","family":"Biichle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Mougey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mercier-Letondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00ebl","family":"Rolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Godet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Perruche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francine","family":"Garnache-Ottou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6522-7252","authenticated-orcid":false,"given":"Mourad","family":"Aribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.116323_bib1","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.116323_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3389\/fendo.2018.00446","article-title":"Metformin, an Anti-diabetic Drug to Target Leukemia","volume":"9","author":"Biondani","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.isci.2026.116323_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s11864-024-01179-3","article-title":"Research Progress on the Use of Metformin in Leukemia Treatment","volume":"25","author":"Wang","year":"2024","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.isci.2026.116323_bib4","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/jcsm.13509","article-title":"Effects of exercise or metformin on myokine concentrations in patients with breast and colorectal cancer: A phase II multi-centre factorial randomized trial","volume":"15","author":"Brown","year":"2024","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.isci.2026.116323_bib5","article-title":"Metformin synergizes with gilteritinib in treating FLT3-mutated leukemia via targeting PLK1 signaling","volume":"5","author":"Chen","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2026.116323_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074420","article-title":"Metformin Induces Apoptosis through AMPK-Dependent Inhibition of UPR Signaling in ALL Lymphoblasts","volume":"8","author":"Leclerc","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.116323_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41419-017-0256-4","article-title":"Metformin exerts multitarget antileukemia activity in JAK2V617F-positive myeloproliferative neoplasms","volume":"9","author":"Machado-Neto","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.116323_bib8","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/leu.2013.107","article-title":"Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells","volume":"27","author":"Scotland","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.116323_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-022-02252-1","article-title":"TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1\u03b1 degradation","volume":"41","author":"Chen","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.116323_bib10","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1038\/leu.2014.64","article-title":"Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition","volume":"28","author":"Sapienza","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.116323_bib11","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1182\/blood-2016-06-724807","article-title":"LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis","volume":"128","author":"Ceroi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116323_bib12","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","article-title":"Targeting PI3K\/AKT\/mTOR network for treatment of leukemia","volume":"72","author":"Bertacchini","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.isci.2026.116323_bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.4161\/cc.11.2.18813","article-title":"Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers","volume":"11","author":"Deng","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.isci.2026.116323_bib14","first-page":"8732","article-title":"Morphoproteomics identifies constitutive activation of the mTORC2\/Akt and NF-\u03baB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: Pathogenetic implications and therapeutic options","volume":"7","author":"Quesada","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.isci.2026.116323_bib15","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4161\/cc.10.13.16244","article-title":"LKB1\/AMPK\/mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology","volume":"10","author":"Green","year":"2011","journal-title":"Cell Cycle"},{"key":"10.1016\/j.isci.2026.116323_bib16","first-page":"2719","article-title":"Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K\/Akt\/mTOR signaling pathway","volume":"17","author":"Li","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.isci.2026.116323_bib17","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1158\/2767-9764.CRC-22-0260","article-title":"Phase I Study of mTORC1\/2 Inhibitor Sapanisertib (CB-228\/TAK-228) in Combination with Metformin in Patients with mTOR\/AKT\/PI3K Pathway Alterations and Advanced Solid Malignancies","volume":"4","author":"Subbiah","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.isci.2026.116323_bib18","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.3324\/haematol.2017.169326","article-title":"Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm","volume":"102","author":"Philippe","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.116323_bib19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature04870","article-title":"Nuclear factor-kappaB in cancer development and progression","volume":"441","author":"Karin","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.116323_bib20","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2026.116323_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2023.100972","article-title":"Repurposing Metformin in hematologic tumor: State of art","volume":"47","author":"Hu","year":"2023","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.isci.2026.116323_bib22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/0300985820948822","article-title":"Human CD34+ Hematopoietic Stem Cell-Engrafted NSG Mice: Morphological and Immunophenotypic Features","volume":"58","author":"Bl\u00fcmich","year":"2021","journal-title":"Vet. Pathol."},{"key":"10.1016\/j.isci.2026.116323_bib23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1158\/2159-8290.CD-16-0999","article-title":"Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax","volume":"7","author":"Montero","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2026.116323_bib24","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/s41467-022-29669-8","article-title":"Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells","volume":"13","author":"Cai","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.116323_bib25","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1182\/bloodadvances.2019000647","article-title":"How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?","volume":"3","author":"Garnache-Ottou","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.116323_bib26","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.2024024262","article-title":"How I treat blastic plasmacytoid dendritic cell neoplasm","volume":"145","author":"Kharfan-Dabaja","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116323_bib27","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.3390\/cancers14153767","article-title":"Conventional Therapeutics in BPDCN Patients\u2014Do They Still Have a Place in the Era of Targeted Therapies?","volume":"14","author":"Poussard","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.116323_bib28","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-09-1186","article-title":"Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug?","volume":"9","author":"Ben Sahra","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.isci.2026.116323_bib29","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.3390\/ijms23052705","article-title":"Metformin and Breast Cancer: Where Are We Now?","volume":"23","author":"Cejuela","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.116323_bib30","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.18632\/aging.102787","article-title":"Metformin: current clinical applications in nondiabetic patients with cancer","volume":"12","author":"Chen","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.isci.2026.116323_bib31","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1038\/cddis.2011.86","article-title":"Metformin inhibits melanoma development through autophagy and apoptosis mechanisms","volume":"2","author":"Tomic","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.116323_bib32","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.3390\/ijms21082907","article-title":"The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells","volume":"21","author":"Nepstad","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.116323_bib33","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1186\/s40001-024-02022-z","article-title":"Network pharmacology-based investigation and experimental validation of the mechanism of metformin in the treatment of acute myeloid leukemia","volume":"29","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.isci.2026.116323_bib34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3390\/biom13020250","article-title":"Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review","volume":"13","author":"Zhang","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.isci.2026.116323_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.867133","article-title":"Metformin and Thymoquinone Synergistically Inhibit Proliferation of Imatinib-Resistant Human Leukemic Cells","volume":"13","author":"Glamoclija","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.isci.2026.116323_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117276","article-title":"Inhibition of mTORC1\/P70S6K pathway by Metformin synergistically sensitizes Acute Myeloid Leukemia to Ara-C","volume":"243","author":"Yuan","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.isci.2026.116323_bib37","doi-asserted-by":"crossref","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","article-title":"Metformin Is an AMP Kinase\u2013Dependent Growth Inhibitor for Breast Cancer Cells","volume":"66","author":"Zakikhani","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116323_bib38","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.isci.2026.116323_bib39","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3390\/genes15050648","article-title":"Metformin as an Enhancer for the Treatment of Chemoresistant CD34+ Acute Myeloid Leukemia Cells","volume":"15","author":"Krastinaite","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.isci.2026.116323_bib40","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1042\/CS20110386","article-title":"Cellular and molecular mechanisms of metformin: an overview","volume":"122","author":"Viollet","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.isci.2026.116323_bib41","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: From Mechanisms of Action to Therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab."},{"key":"10.1016\/j.isci.2026.116323_bib42","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.7150\/jca.60208","article-title":"Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia","volume":"12","author":"Zhou","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.isci.2026.116323_bib43","article-title":"Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR\/AKT signaling","volume":"54","author":"Lu","year":"2019","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.isci.2026.116323_bib44","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1080\/15384101.2020.1743911","article-title":"Metformin activates AMPK\/SIRT1\/NF-\u03baB pathway and induces mitochondrial dysfunction to drive caspase3\/GSDME-mediated cancer cell pyroptosis","volume":"19","author":"Zheng","year":"2020","journal-title":"Cell Cycle"},{"key":"10.1016\/j.isci.2026.116323_bib45","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/s41598-019-39556-w","article-title":"Metformin and glucose starvation decrease the migratory ability of hepatocellular carcinoma cells: targeting AMPK activation to control migration","volume":"9","author":"Ferretti","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.116323_bib46","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-02-269837","article-title":"The LKB1\/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.116323_bib47","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level","volume":"27","author":"Sahra","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.116323_bib48","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1172\/JCI43661","article-title":"An energetic tale of AMPK-independent effects of metformin","volume":"120","author":"Miller","year":"2010","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.116323_bib49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3892\/mmr.2020.11725","article-title":"Metformin induces apoptosis and inhibits migration by activating the AMPK\/p53 axis and suppressing PI3K\/AKT signaling in human cervical cancer cells","volume":"23","author":"Chen","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.isci.2026.116323_bib50","first-page":"299","article-title":"Targeting the PI3K\/AKT\/mTOR Signaling Axis in Children with Hematologic Malignancies","volume":"14","author":"Barrett","year":"2012","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.isci.2026.116323_bib51","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1517\/14728222.2014.924507","article-title":"AKT as a therapeutic target in multiple myeloma","volume":"18","author":"Keane","year":"2014","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.isci.2026.116323_bib52","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2009.010272","article-title":"Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition","volume":"95","author":"Zhuang","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.116323_bib53","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/leu.2014.156","article-title":"Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia","volume":"29","author":"Schafranek","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.116323_bib54","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccr.2008.05.005","article-title":"Tumor Cell Metabolism: Cancer\u2019s Achilles\u2019 Heel","volume":"13","author":"Kroemer","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.116323_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1126\/science.123.3191.309","article-title":"On the origin of cancer cells","volume":"123","author":"Warburg","year":"1956","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.116323_bib56","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1158\/0008-5472.CAN-06-4447","article-title":"Systemic Treatment with the Antidiabetic Drug Metformin Selectively Impairs p53-Deficient Tumor Cell Growth","volume":"67","author":"Buzzai","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2026.116323_bib57","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/JME-12-0007","article-title":"Metformin in cancer: translational challenges","volume":"48","author":"Dowling","year":"2012","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.isci.2026.116323_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2012.13","article-title":"Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy","volume":"3","author":"Shi","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.116323_bib59","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.3390\/cancers14174215","article-title":"Activation of the Anaphase Promoting Complex Reverses Multiple Drug Resistant Cancer in a Canine Model of Multiple Drug Resistant Lymphoma","volume":"14","author":"Arnason","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.116323_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215582","article-title":"Metformin sensitizes AML cells to chemotherapy through blocking mitochondrial transfer from stromal cells to AML cells","volume":"532","author":"You","year":"2022","journal-title":"Cancer Lett."},{"key":"10.1016\/j.isci.2026.116323_bib61","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1073\/pnas.1417636112","article-title":"Immune-mediated antitumor effect by type 2 diabetes drug, metformin","volume":"112","author":"Eikawa","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.116323_bib62","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3324\/haematol.2018.202093","article-title":"Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target","volume":"104","author":"Sapienza","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.116323_bib63","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1182\/bloodadvances.2021006306","article-title":"Loss of METTL3 attenuates blastic plasmacytoid dendritic cell neoplasm response to PRMT5 inhibition via IFN signaling","volume":"6","author":"Rethnam","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2026.116323_bib64","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/eji.200324531","article-title":"Leukemic plasmacytoid dendritic cells share phenotypic and functional features with their normal counterparts","volume":"34","author":"Chaperot","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2026.116323_bib65","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ccr.2011.12.029","article-title":"Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells","volume":"21","author":"Tsai","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.isci.2026.116323_bib66","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12772","article-title":"Metformin directly targets the H3K27me3 demethylase KDM6A\/UTX","volume":"17","author":"Cuy\u00e0s","year":"2018","journal-title":"Aging Cell"},{"key":"10.1016\/j.isci.2026.116323_bib67","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/bjh.18968","article-title":"Metformin sensitizes AML cells to venetoclax through endoplasmic reticulum stress\u2014CHOP pathway","volume":"202","author":"Hua","year":"2023","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.isci.2026.116323_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/jha2.70070","article-title":"Venetoclax in the Therapeutic Strategy for BPDCN Management","volume":"6","author":"Poussard","year":"2025","journal-title":"EJHaem"},{"key":"10.1016\/j.isci.2026.116323_bib69","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3390\/cancers17020221","article-title":"A Multidisciplinary Approach to Diagnosing Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Practical Recommendations and Insights from Countries of the Gulf Cooperation Council","volume":"17","author":"Bakshi","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2026.116323_bib70","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1532\/IJH97.04116","article-title":"A novel plasmacytoid dendritic cell line, CAL-1, established from a patient with blastic natural killer cell lymphoma","volume":"81","author":"Maeda","year":"2005","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.isci.2026.116323_bib71","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1365-2141.2009.07679.x","article-title":"Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia","volume":"145","author":"Garnache-Ottou","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.isci.2026.116323_bib72","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.isci.2026.116323_bib73","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/bjh.15128","article-title":"Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations","volume":"181","author":"Kurt","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.isci.2026.116323_bib74","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.3390\/jcm14103432","article-title":"Porcine Peripheral Blood Mononuclear Cells (PBMCs): Methods of Isolation, Cryopreservation, and Translational Applications in Human Studies","volume":"14","author":"Pietrzak","year":"2025","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.isci.2026.116323_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102405","article-title":"A protocol for high-throughput screening for immunomodulatory compounds using human primary cells","volume":"4","author":"Chew","year":"2023","journal-title":"STAR Protoc."},{"key":"10.1016\/j.isci.2026.116323_bib76","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the Human Immunology Project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.116323_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1202017","article-title":"Characterization of atypical T cells generated during ex vivo expansion process for T cell-based adoptive immunotherapy","volume":"15","author":"Mercier-Letondal","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.116323_bib78","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1471-2105-7-123","article-title":"Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate","volume":"7","author":"Motulsky","year":"2006","journal-title":"BMC Bioinf."},{"key":"10.1016\/j.isci.2026.116323_bib79","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/pst.426","article-title":"Guidelines for accurate EC50\/IC50 estimation","volume":"10","author":"Sebaugh","year":"2011","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.isci.2026.116323_bib80","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.3324\/haematol.2015.135459","article-title":"The anti-inflammatory effects of platelet-derived microparticles in human plasmacytoid dendritic cells involve liver X receptor activation","volume":"101","author":"Ceroi","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2026.116323_bib81","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/blood.V88.8.3230.bloodjournal8883230","article-title":"An Experimental Model of Idiopathic Pneumonia Syndrome After Bone Marrow Transplantation: I. The Roles of Minor H Antigens and Endotoxin","volume":"88","author":"Cooke","year":"1996","journal-title":"Blood"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226016986?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226016986?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:57:52Z","timestamp":1788224272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226016986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":81,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2589004226016986"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.116323","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin dual-targets metabolism and survival pathways in BPDCN","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.116323","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116323"}}